2-[4-(4-Furan-2-yl-phenyl)piperazine-1-sulfonylmethyl]-N-hydroxy-3-methyl butyramide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[4-(4-Furan-2-yl-phenyl)piperazine-1-sulfonylmethyl]-N-hydroxy-3-methyl butyramide
• 英文别名: 2-[4-(4-furan-2-yl-phenyl)piperazine-1-sulfonylmethyl]-N-hydroxy-3-methylbutyramide；2-[[4-[4-(furan-2-yl)phenyl]piperazin-1-yl]sulfonylmethyl]-N-hydroxy-3-methylbutanamide
• 化学式: C₂₀H₂₇N₃O₅S
• 分子量: 421.517
• InChiKey: BNZZGYWZOWCJKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-[4-(4-Furan-2-yl-phenyl)piperazine-1-sulfonylmethyl]-N-hydroxy-3-methyl butyramide 、 4-[4-(4-Bromophenyl)piperazine-1-sulfonylmethyl]tetrahydropyran-4-carboxylic acid 以to yield the title compound as a white solid (4.07 g, 87%)的产率得到4-[4-(4-Bromophenyl)piperazine-1-sulfonylmethyl]-tetrahydropyran-4-carboxylic acid hydroxyamide
  参考文献：
  名称：

  Hydroxamic acid derivatives

  摘要：

  本发明涵盖了一些新型化合物，这些化合物是基质金属蛋白酶、ADAM或ADAM-TS酶的抑制剂，可以用于治疗由这些酶介导的疾病，包括退行性疾病和某些癌症。

  公开号：

  US06787536B2
• 作为产物：
  描述：

  4-[4-(4-Pyridin-3-yl-phenyl)piperazine-1-sulfonylmethyl]-tetrahydropyran-4-carboxylic acid 以94%的产率得到4-[4-(4-Pyridin-3-yl-phenyl)piperazine-1-sulfonylmethyl]-tetrahydropyran-4-carboxylic acid-N-hydroxyamide
  参考文献：
  名称：

  US2002/37900

  摘要：

  公开号：

文献信息

• HYDROXAMIC ACID DERIVATIVES
  申请人：Darwin Discovery Limited

  公开号：EP1282614B1

  公开（公告）日：2003-11-12
• US6787536B2
  申请人：——

  公开号：US6787536B2

  公开（公告）日：2004-09-07
• US6809100B2
  申请人：——

  公开号：US6809100B2

  公开（公告）日：2004-10-26
• [EN] HYDROXAMIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDE HYDROXAMIQUE
  申请人：DARWIN DISCOVERY LTD

  公开号：WO2001087870A1

  公开（公告）日：2001-11-22

  A compound of formula (I) wherein R2 is H, alkyl, alkenyl, alkynyl, aryl, araylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclo, heterocycloalkyl or cycloalkyl (any of which may be optionally substituted with one or more substituents selected from R4, W and WR4); and R3 is H or alkyl; or R2, R3 and the carbon atom to which they are attached together represent a carbocyclic or heterocyclic ring (either of which may be substituted with one or more substituents chosen from R4, W and WR4); A is heterocyclic ring (attached to SO¿2? through a nitrogen atom) optionally substituted with R?4¿; B is an aryl or heteroaryl ring, optionally substituted with one or more R5; D is an aryl or heteroaryl ring, optionally substituted with one or more R5, or a heterocyclic ring (attached through a carbon atom) optionally substituted with R4 at any available carbon atom or with R14 at any available nitrogen atom; provided that B aand D are not both phenyl; R?4 is OR6, COR10, CO¿2R?9, CONR7R8, NR10R11¿, S(O)¿qR?10, S(O)¿qNR?7R8, CN, =O or =NOR10, provided that R4 is not =O or =NOR10 if a substituent on an aromatic ring; R5 is alkyl, cycloalkyl, CF¿3?, OR?6, COR10¿, S(O)¿q?R?10, CO¿2R?9, CONR7R8¿, S(O)¿qNR?7R8, halogen, NR10R11 or CN; R6 is H, alkyl, CF¿3?, CHF2, CH2F, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl; R?7 and R8¿, which may be the same or different, are each H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl, cycloalkylalkyl, or R?7 and R8¿ and the nitrogen to which they are attached together represent a heterocyclic ring; R9 is H, alkyl or cycloalkyl; R10 is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl; and R11 is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroalrylalkyl, heterocycloalkyl, cycloalkylalkyl, COR?12, CONR7R8¿, S(O)¿qR?12 or S(O)¿q?NR?7R8; or R10 and R11¿ and the nitrogen atom to which they are attached together represent a heterocyclic ring optionally substituted by R?13; R12 is OR6 or R13; R13¿ is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl; R14 is H, alkyl or cycloalkyl; q is 0, 1 or 2; W is alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclo or heterocycloalkyl; and X is -O-, -CO-, S(O)¿q?-, -N(R?10¿)-, or is absent; or a salt, solvate, hydrate, N-oxide, protected amino, protected carboxy or protected hydroxamic acid derivative thereof.
• Hydroxamic acid derivatives
  申请人：——

  公开号：US20030216404A1

  公开（公告）日：2003-11-20

  The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers.

  本发明涵盖了一些新型的化合物，这些化合物是基质金属蛋白酶、ADAM或ADAM-TS酶的抑制剂，并且对于治疗由这些酶介导的疾病，包括退行性疾病和某些癌症，具有有益的作用。